Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib

Arthritis Care and Research

Volumn 13, Issue 2, 2000, Pages 112-121

  Zhao, Sean Z ^a   Fiechtner, Justus I ^b   Tindall, Elizabeth A ^c   Dedhiya, Seema D ^a   Zhao, William W ^a   Osterhaus, Jane T ^a   Yu, Shawn S ^a  

^a PFIZER INC   (United States)

^b Good Clinical Practice Michigan Corp   (United States)

^c Portland Medical Associates   (United States)

Author keywords

Functional status; Health related quality of life; Medical Outcomes Study Short Form 36; Rheumatoid arthritis; Stanford Health Assessment Questionnaire

Indexed keywords

CELECOXIB; NAPROXEN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EVALUATION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHYSICAL DISABILITY; PHYSICAL PERFORMANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 0033808692     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200004)13:2<112::aid-anr5>3.0.co;2-l     Document Type: Article

References (48)

1. Current management of rheumatoid arthritis
2. Direct medical costs unique to people with arthritis
3. Rehabilitation advances in the treatment of arthritis and musculo-skeletal disease
4. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs
5. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs
6. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
7. Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function
8. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure
9. Renal complications of nonsteroidal anti-inflammatory drugs
10. Nonsteroidal anti-inflammatory drugs and antihypertensives
11. Inhibition of platelet prostaglandin synthetase by oral aspirin
12. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
13. Special considerations in the use of NSAIDs in the elderly
14. Effects of non-steroidal anti-inflammatory drugs on fatty acid cyclo-oxygenase and prostaglandin hydroperoxidase activities
15. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic
16. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain
17. PGH synthase isoenzyme selectivity: The potential for safer nonsteroidal antiinflammatory drugs
18. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
19. Synthesis and biological evaluation of the 1,5-diary pyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib)
20. Efficacy of cyclosporin A in rheumatoid arthritis: Long-term follow-up data and the effect on quality of life
21. The relationship between clinical activity and depression in rheumatoid arthritis
22. The clinical value of the Stanford Health Assessment Questionnaire functional disability index in patients with rheumatoid arthritis
23. A comparison of disability measured by the Stanford Health Assessment Questionnaire disability scales (HAQ) in male and female rheumatoid outpatients
24. Measurement of patient outcome in arthritis
25. Validity and discriminant ability of the HAQ functional index in early rheumatoid arthritis
26. Comparison of two approaches to measuring change in health status in rheumatoid arthritis: The Health Assessment Questionnaire (HAQ) and modified HAQ
27. Are we making the most of the Stanford Health Assessment Questionnaire?
28. Sensitivity to change of the Health Assessment Questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis: Results of short-term clinical trials and observational studies versus long-term observational studies
29. Use of the Short Form 36 (SF36) for health status measurement in rheumatoid arthritis
30. The dimensions of health outcomes: A cross-validated examination of health status measurement
31. The measurement of health status and quality of life in rheumatological disorders
32. Comparison of the Musculoskeletal Function Assessment questionnaire with the Short Form-36, the Western Ontario and McMaster Universities Osteoarthritis Index, and the Sickness Impact Profile health-status measures
33. The MOS 36-item short-form health survey (SF-36). III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups
34. Measuring health status in British patients with rheumatoid arthritis: Reliability, validity and responsiveness of the Short Form 36-item health survey (SF-36)
35. What is the best way of assessing outcome after total knee replacement?
36. Comparative measurement sensitivity of short and longer health status instruments
37. The SF-36 health survey (SF-36) as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: Relative validity of scales in relation to clinical measures of arthritis severity
38. The responsiveness of health status measures in patients with rheumatoid arthritis: Comparison of disease-specific and generic instruments
39. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
40. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis
41. The anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized, controlled trial
42. The Health Assessment Questionnaire 1995 - Status and review
43. A comparison of the random-effects pattern mixture model with last-observation-carried-forward (LOCF) analysis in longitudinal clinical trials with dropouts
44. A sharper Bonferroni procedure for multiple tests of significance
45. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib
46. Predicting health care use among older osteoarthritis patients in an HMO